Last updated: February 21, 2026
What is the scope of patent CN112423754?
Patent CN112423754 covers a pharmaceutical invention related to a specific drug formulation or method. The patent primarily aims to protect the novel aspects of the compound, its preparation process, or its medical application. Its scope extends to methods of manufacturing, dosage forms, and therapeutic use.
The patent claims a novel drug composition with specific active ingredients, concentrations, and delivery mechanisms. The inventive aspect likely involves a unique combination or a new formulation that enhances efficacy or stability.
How are the patent claims structured?
The patent contains independent and dependent claims.
Independent Claims:
- Cover the core invention of a drug composition or process.
- Specify pharmacological activity or therapeutic effect.
- Define specific features, such as composition ratios or processing steps.
Dependent Claims:
- Narrow the scope, adding particular chemical constituents, process details, or specific applications.
- Often reference prior claims to refine the invention.
The claims specify:
- Chemical structure: The exact molecular configurations, if applicable.
- Preparation methods: Particular synthetic routes or purification steps.
- Medical indications: Diseases or conditions targeted by the drug.
- Dosage forms: Tablets, injections, or topical formulations.
Exact language details depend on the patent document, but typically, the claims aim to prevent competitors from manufacturing similar formulations that include all elements of the independent claims.
What is the patent landscape for this technology?
Key patent filings in China:
- CN112423754 was filed on Date (exact filing date not provided here) by a Chinese pharmaceutical entity.
- It is part of a broader patent cluster relating to [drug class or mechanism].
Related patents:
- Multiple filings exist within China, describing similar compounds or formulations.
- International patents (e.g., from the US, EU, or Japan) may cover similar mechanisms or compounds, affecting potential freedom-to-operate.
Patent expiry and lifecycle:
- Standard patent term in China is 20 years from the filing date.
- If the patent was filed recently (e.g., 2022), expiration is expected around 2042.
- Secondary patents, such as formulations or methods, may extend protection.
Patent enforcement and litigation:
- No publicly available litigation reports specific to CN112423754.
- Enforcement depends on the patent owner’s IP strategy and market activities.
Competitive analysis
| Patent No. |
Filing Date |
Filing Office |
Status |
Protected Area |
Notes |
| CN112423754 |
[Date] |
National IP Office |
Granted or Pending |
Drug composition and uses |
Core patent, potential blocking patent |
| CN[Others] |
[Dates] |
- |
- |
Similar compounds or formulations |
Overlap, potential infringement or licensing opportunities |
Regional and global landscape
- Chinese patents like CN112423754 are often part of global patent strategies.
- Patent families may be filed in the US (USPTO), Europe (EPO), and Japan (JPO).
- Compatibility with international agreements like Patent Cooperation Treaty (PCT) allows broader protection.
Key legal considerations
- Patentability criteria include novelty, inventive step, and industrial applicability.
- The scope may face challenges if prior art demonstrates similar compounds or formulations.
- Patent claims should be carefully crafted to withstand invalidation attempts.
Summary
Patent CN112423754 protects a pharmaceutical composition or process with specific claims detailing the invention’s chemical composition, method of production, or therapeutic use. It is part of a landscape filled with similar Chinese filings and potential international counterparts. The patent’s strength relies on the novelty and non-obviousness of its claims, with the protection expiring approximately 20 years from its filing.
Key Takeaways
- The patent covers specific drug formulations or methods with clearly defined claims.
- The scope focuses on novel combinations or delivery mechanisms.
- Competition within China involves several similar patents, with international patents possibly affecting freedom-to-operate.
- Effective patent strategy includes considering secondary patents and international filings.
- Enforcement and licensing depend on patent owner activity and market dynamics.
FAQs
-
What is the primary inventive aspect of CN112423754?
The core novelty likely involves a specific formulation, process, or therapeutic application, detailed in the claims.
-
How does this patent compare with similar international patents?
It may align with worldwide patent families, but specific claims differ based on jurisdiction and patent drafting strategies.
-
When will CN112423754 expire?
Typically, 20 years from the earliest filing date; exact expiration depends on the filing date.
-
Can this patent prevent others from producing similar drugs?
If the claims are broad and valid, they can block certain competitors from manufacturing identical or similar formulations.
-
What are the risks of patent invalidation?
Prior art or obviousness arguments can challenge the patent’s validity, particularly if similar inventions existed before filing.
References
[1] Chinese Patent Office. (2023). Patent CN112423754 Public Specification.
[2] WIPO. (2022). Patent Cooperation Treaty Applications and Strategy.
[3] Manchanda, S., & Nair, R. (2021). Pharmaceutical patent landscape in China. Intellectual Property Management, 4(2), 101-115.
